Drug interactions
Daunorubicin + Trastuzumab deruxtecan
Severity: Major
Daunorubicin and Trastuzumab deruxtecan: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Anthracyclines and HER2-directed antibodies both carry cardiotoxicity risk, and giving them together or in close sequence increases the risk of cardiomyopathy and reduced ejection fraction. Trastuzumab deruxtecan also causes interstitial lung disease and myelosuppression.
What this interaction means in plain words
Daunorubicin and Trastuzumab deruxtecan can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Daunorubicin belongs to Oncology; Trastuzumab deruxtecan belongs to Oncology.
Why it happens
Additive cardiotoxicity from anthracycline myocardial injury and HER2 pathway inhibition in cardiomyocytes.
What to do
Avoid concurrent use and keep the interval between anthracycline and HER2-directed therapy as long as possible. Assess left ventricular ejection fraction before and regularly during treatment.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Daunorubicin and Trastuzumab deruxtecan, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Daunorubicin
- Adenovirus types 4 and 7 live + Daunorubicin Contraindicated
- Belatacept + Daunorubicin Major
- Cyclosporine + Daunorubicin Major
- Cyclosporin + Daunorubicin Major
- Daunorubicin + Dengue vaccine Major
- Daunorubicin + Etrasimod Major
Other interactions of Trastuzumab deruxtecan
Frequently asked questions
Can I take Daunorubicin with Trastuzumab deruxtecan?
MediHelp rates the interaction as major. Daunorubicin and Trastuzumab deruxtecan can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Anthracyclines and HER2-directed antibodies both carry cardiotoxicity risk, and giving them together or in close sequence increases the risk of cardiomyopathy and reduced ejection fraction. Trastuzumab deruxtecan also causes interstitial lung disease and myelosuppression.
How serious is the interaction between Daunorubicin and Trastuzumab deruxtecan?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use and keep the interval between anthracycline and HER2-directed therapy as long as possible. Assess left ventricular ejection fraction before and regularly during treatment.
What other medicines interact with Daunorubicin?
MediHelp also lists interactions of Daunorubicin with, for example, Adenovirus types 4 and 7 live, Belatacept, Cyclosporine. The full list is on the Daunorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
